Non‐genetic risk factors and predicting efficacy for docetaxel–drug‐induced liver injury among metastatic breast cancer patients
Authors:
- 20 March 2012
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (8) , 1348-1352
Abstract
Background and Aim: Docetaxel has been chosen as one of the most popular anticancer drugs in the treatment of breast cancer for more than a decade. There is increasingly awareness for the occurrence of docetaxel and/or docetaxel–drug‐induced liver injury (DILI), although the underlying mechanism of occurrence and its risk factors remain unclear.Methods: We conducted a retrospective cohort study to identify non‐genetic risk factors for docetaxel–DILI among 647 metastasis breast cancer patients treated with docetaxel‐containing regimens.Results: Sixty‐seven (10.36%) patients were diagnosed as docetaxel–DILI. By logistic regression analysis, premenopausal status (odds ratio [OR][95% confidence interval {CI}] = 2.24 [1.30–3.87]), past hepatitis B virus (HBV) infections (OR [95% CI] = 4.23 [1.57–11.42]), liver metastasis (OR [95% CI] = 3.70 [2.16–6.34]). The predominant occurrence of DILI was seen in groups with docetaxel combination regimens. (OR [95% CI] = 2.66 [1.59–4.55]). The potential increasing occurrence of docetaxel–DILI was associated with multiple risk factors in an exposure–response manner (P < 0.001), and patients with more than three risk factors would be exposed to a 36.61‐fold risk of DILI (95% CI = 10.18–131.62). Further analysis by the risk score and area under the receiver–operator characteristic curve (AUC) showed that those four factors contributed to an AUC of 0.7536 (95% CI = 0.70–0.81), with a predictive sensitivity of 74.63% and specificity of 65.17%.Conclusions: Docetaxel–DILI with a relatively higher incidence should be addressed among metastatic breast cancer patients. Four predominant risk factors, including premenopausal status, past HBV infection, liver metastasis, and docetaxel combination regimens, were potential predicators for DILI.Keywords
This publication has 25 references indexed in Scilit:
- Risk Factors for Idiosyncratic Drug-Induced Liver InjuryGastroenterology, 2010
- Genetic Association Studies in Drug-Induced Liver InjurySeminars in Liver Disease, 2009
- Epidemiology of Idiosyncratic Drug-Induced Liver InjurySeminars in Liver Disease, 2009
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- Phenotypic characterization of idiosyncratic drug‐induced liver injuryHepatology, 2009
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver diseaseHepatology Research, 2007
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Criteria of drug-induced liver disordersJournal of Hepatology, 1990